Abstract: In certain embodiments, the invention stems from the discovery that analysis of population distribution curves of metabolite levels in blood can be used to facilitate predicting risk of autism spectrum disorder (ASD) and/or to differentiate between ASD and non-ASD developmental delay (DD) in a subject. In certain aspects, information from assessment of the presence, absence, and/or direction (upper or lower) of a tail effect in a metabolite distribution curve is utilized to predict risk of ASD and/or to differentiate between ASD and DD.
Type:
Grant
Filed:
February 27, 2015
Date of Patent:
November 3, 2015
Assignee:
SynapDx Corporation
Inventors:
Ute Geigenmuller, Doris Damian, Maciej Pacula, Mark A. DePristo
Abstract: Methods and systems are presented herein to distinguish children with Autism Spectrum Disorders (ASD) from those with other forms of developmental delay (DD) based on patterns of gene expression levels in blood.
Abstract: The present disclosure generally provides methods for normalizing gene expression profiles against a cellular repertoire, i.e., the different proportions of various cell types in a sample containing multiple cell types. More specifically, the present disclosure encompasses a method for normalizing the gene expression profile against a mixed cell population.